SCHEMBL108422

SCHEMBL108422

Nc1ccc(S(N)(=O)=O)c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.64
CA2 P00918 4/20 0.56
CA1 P00915 3/20 0.56
CA9 Q16790 2/20 0.56
CA4 P22748 2/20 0.56
CA6 P23280 2/20 0.56
CYP2C9 P11712 2/20 0.56
CA12 O43570 1/20 0.56
CA5A P35218 1/20 0.56
CA7 P43166 1/20 0.56
CA14 Q9ULX7 1/20 0.56
CA5B Q9Y2D0 1/20 0.56
CDK2 P24941 1/20 0.53
TTR P02766 1/20 0.52
HDAC3 O15379 1/20 0.50
IDO1 P14902 1/20 0.50
EP300 Q09472 1/20 0.50
KAT2B Q92831 1/20 0.50
KAT8 Q9H7Z6 1/20 0.50
NCOR2 Q9Y618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1803500 0.87 TTR (0.68) LDHACA2CA1CA9CA4
SCHEMBL532349 0.83 TTR (0.48) LDHACA2CA1CA9CA4
SCHEMBL150853 0.81 TTR (0.78) LDHATTRHDAC3IDO1EP300
SCHEMBL29516385 0.81 TTR (0.78) LDHATTRHDAC3IDO1EP300
SCHEMBL636440 0.81 TTR (0.50) LDHACA2CA1CA9CA4
SCHEMBL19922628 0.81 TTR (0.50) LDHACA2CA1CA9CA4
SCHEMBL1525888 0.81 TTR (0.78) LDHATTRHDAC3IDO1EP300
SCHEMBL10730555 0.81 TTR (0.50) LDHACA2CA1CA9CA4
SCHEMBL31603821 0.81 TTR (0.50) LDHATTRHDAC3IDO1EP300
SCHEMBL38143 0.81 TTR (0.50) LDHACA2CA1CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1014 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023164252-A1 ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2023-08-31 WO claimed
CN-105940083-B Light wavelength conversion element containing ionic liquid and the article comprising the light wavelength conversion element 日本化药株式会社 2019-06-11 CN claimed
CN-109342381-A A kind of fluorescent dyeing reagent 广州往圣生物科技有限公司 2019-02-15 CN claimed
US-9915665-B2 High-throughput system and method for identifying antibodies having specific antigen binding activities ABBVIE INC. (US) 2018-03-13 US claimed
US-9546247-B2 Explosive detection polymer comprising functionalized polyamine polymers and methods of using the same UNIVERSITY OF CONNECTICUT (US) 2017-01-17 US claimed
US-20160245757-A1 A Method of Controlling Hydrophobic Contaminants by Utilizing a Fluorescent Dye ECOLAB USA INC. (US) 2016-08-25 US claimed
EP-3049807-A1 A METHOD OF CONTROLLING HYDROPHOBIC CONTAMINANTS BY UTILIZING A FLUORESCENT DYE Ecolab USA Inc. (US) 2016-08-03 EP claimed
EP-2938636-A2 HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES AbbVie Inc. (US) 2015-11-04 EP claimed
WO-2015048241-A1 A METHOD OF CONTROLLING HYDROPHOBIC CONTAMINANTS BY UTILIZING A FLUORESCENT DYE ECOLAB USA INC. (US) 2015-04-02 WO claimed
US-20150056711-A1 Explosive Detection Polymer Comprising Functionalized Polyamine Polymers and Methods of Using the Same UNIVERSITY OF CONNECTICUT (US) 2015-02-26 US claimed
US-20140243228-A1 HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES ABBVIE, INC. (US) 2014-08-28 US claimed
WO-2014106004-A2 HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES ABBVIE, INC. (US) 2014-07-03 WO claimed
WO-2013165625-A2 EXPLOSIVES DETECTION POLYMER COMPRISING FUNCTIONALIZED POLYAMINE POLYMERS AND METHODS OF USING THE SAME UNIVERSITY OF CONNECTICUT (US) 2013-11-07 WO claimed
WO-2013070943-A2 SMALL MOLECULE SCREEN FOR INHIBITORS OF NFAT:AP-1:DNA INTERACTIONS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2013-05-16 WO claimed
WO-2026107198-A1 ANTIBODY BIOMARKER TO DIAGNOSE IDIOPATHIC INFLAMMATORY MYOPATHIES OHIO STATE INNOVATION FOUNDATION (US) 2026-05-21 WO disclosed
EP-4739790-A1 METHODS AND COMPOSITIONS FOR STABILIZING CONCATEMERS Pacific Biosciences of California, Inc. (US) 2026-05-13 EP disclosed
US-20260125675-A1 DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY H LEE MOFFITT CANCER CENTER AND RESEARCH INST INC (US) 2026-05-07 US disclosed
US-4001253-A NAPHTHOLACTAM DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1977-01-04 US disclosed
US-3978037-A POLYAMIDES CIBA-GEIGY CORPORATION (US) 1976-08-31 US disclosed
US-3950347-A NAPHTHOLACTAM DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125675-A1 DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY PDCD1LG2, TRMT1L, TTLL12 LDHA 2661/4885CA2 3352/4885CA1 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.